Growth hormone secretagogues and receptor selectivity
In a phase 2 clinical trial targeting obese individuals without type 2 diabetes (T2D), retatrutide dosed at 1 to 12 mg resulted in up to 24.2% weight loss over a 48-week treatment period, compared to 2.1% in the placebo group, and demonstrated a dose-dependent effect
Gwne przeciwwskazania: Nadwraliwo na jakikolwiek skadnik preparatu, cukrzyca typu 1, cukrzycowa kwasica ketonowa, cika zastoinowa niewydolno serca (NYHA IV), schykowa niewydolno nerek, ostre zapalenie trzustki wywoane dotychczasow terapi lekiem Ozempic Gwne dziaania niepodane: Wymioty, nudnoci, biegunka, zwikszona aktywno amylazy Ozempic - cena Za opakowanie leku Ozempic naley zapaci ok
The Changing Treatment Paradigm Retatrutides arrival will likely shift how physicians and patients think about obesity treatment
However, as with any medical intervention, there are important contraindications to consider